Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Molecular and Clinical Oncology|April 8, 2020
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report seriesFrancesco Schettini, Irene De Santo, Carmen G Rea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd TrialAmelia McCartney, Martina Bonechi, Francesca De Luca, et al.
European Journal of Cancer (Oxford, England : 1990)|May 7, 2019
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)Amelia McCartney, Chiara Biagioni, Gaia Schiavon, et al.
Breast Cancer Research : BCR|March 25, 2021
Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trialFrancesca Galardi, Francesca De Luca, Chiara Biagioni, et al.
Breast Cancer Research : BCR|May 31, 2019
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trialLorenzo Rossi, Chiara Biagioni, Amelia McCartney, et al.
Cancers|July 2, 2021
A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant SettingSamantha Di Donato, Alessia Vignoli, Chiara Biagioni, et al.
European Journal of Cancer (Oxford, England : 1990)|November 10, 2024
Prospective study on Oncotype DX® assay to assess recurrence risk in early ER-positive HER2-negative breast cancer patients with uncertain biological behavior by standard parameters and its impact on treatment recommendation: The POST trialLuca Livraghi, Francesca Martella, Matteo Ghilli, et al.
European Journal of Cancer (Oxford, England : 1990)|April 1, 2023
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trialLuca Malorni, Giampaolo Bianchini, Roberta Caputo, et al.
Molecular Cancer Research : MCR|March 12, 2016
Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes ResistanceLuca Malorni, Mario Giuliano, Ilenia Migliaccio, et al.
Eclinicalmedicine|October 13, 2025
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer: a systematic review and network meta-analysisRoberto Buonaiuto, Mario Fordellone, Aldo Caltavituro, et al.
Pageof 7